


HEALTHCARE

## **Patent Protection Strategies**

Maximising Product Revenues

By Peter Norman

 [Table of Contents](#)

## **Peter Norman MBA, PhD**

Peter Norman is a pharmaceutical consultant and analyst based in Burnham Beeches, near Windsor, England, with specialist knowledge of the respiratory disease and inflammation markets. He has written and presented widely on various aspects of respiratory disease and on the analysis of therapeutic markets.

Dr. Norman has over 25 years' experience of the pharmaceutical industry in both R&D and competitive intelligence. His publications include many reviews and management reports, sixteen original scientific papers and eleven patents. Dr. Norman holds science degrees from Cambridge University and Brunel University plus an M.B.A. degree from the Open University.

Copyright © 2007 Business Insights Ltd  
This Management Report is published by Business Insights Ltd. All rights reserved.  
Reproduction or redistribution of this Management Report in any form for any purpose is expressly prohibited without the prior consent of Business Insights Ltd.

The views expressed in this Management Report are those of the publisher, not of Business Insights. Business Insights Ltd accepts no liability for the accuracy or completeness of the information, advice or comment contained in this Management Report nor for any actions taken in reliance thereon.

While information, advice or comment is believed to be correct at the time of publication, no responsibility can be accepted by Business Insights Ltd for its completeness or accuracy.

# Table of Contents

## **PATENT PROTECTION STRATEGIES**

<b>Executive Summary</b>	<b>10</b>	
<b>The need for patent protection</b>	<b>10</b>	
<b>Current patent protection mechanisms</b>	<b>10</b>	
<b>Offensive strategies</b>	<b>12</b>	
<b>Case Histories</b>	<b>13</b>	
<b>Optimizing Revenue Returns</b>	<b>14</b>	
<b>Future outlook</b>	<b>15</b>	
<b>Chapter 1</b>	<b>The need for patent protection</b>	<b>18</b>
<b>Summary</b>		<b>18</b>
<b>Introduction</b>		<b>19</b>
The costs of drug development		19
The drug lifecycle		21
The need to optimize returns from successful drugs		22
The dependence on blockbuster revenues		23
The impact of generics		25
Aggressive generic companies		30
<b>Chapter 2</b>	<b>Current patent protection mechanisms</b>	<b>34</b>
<b>Summary</b>		<b>34</b>
<b>Introduction</b>		<b>35</b>
<b>Patent basics</b>		<b>35</b>
Requirements for a therapeutic patent		36
Four types of pharmaceutical patent		37
<b>Legal patent frameworks</b>		<b>38</b>
United States		38
Europe/PCT		40

Japan	41
Other markets	41
<b>Patent term extensions</b>	<b>42</b>
US patent term extensions	43
Supplementary Protection Certificates	44
Japanese Patent term extensions	46
Pediatric exclusivity	46
<b>Orphan Drug legislation</b>	<b>48</b>
<b>Regulations for market entry of generics</b>	<b>51</b>
United States	52
Hatch Waxman	52
ANDAs	52
Paragraph IV challenges	54
Europe	55
Japan	55
<b>Biological Products and Biosimilars</b>	<b>57</b>
United States	59
Europe	61
<b>Freedom to operate</b>	<b>62</b>

## **Chapter 3                      Offensive strategies                      66**

<b>Summary</b>	<b>66</b>
<b>Introduction</b>	<b>67</b>
<b>Filing strategies</b>	<b>68</b>
Early or late filing?	68
Overlapping claims	69
Broad claims or narrow claims?	71
<b>Exploitation of term extension legislation</b>	<b>73</b>
<b>Product patents</b>	<b>75</b>
Subsidiary patents	76
Crystalline form patents	78
Salt and solvate patents	80
Enantiomer patents	82
Prodrug and antedrug patents	82
<b>Process patents</b>	<b>84</b>
<b>Formulation patents</b>	<b>85</b>
Improved formulations	85
Drug Combinations	87
"Obvious" antihypertensive combinations	87
Advair	88
Antidiabetic agents	89
New delivery routes	89
<b>Method of Use patents</b>	<b>90</b>

## **Chapter 4                      Defensive strategies                      94**

Summary	94
Introduction	95
Patent infringement suits	96
Mechanism	96
Authorized generics	100
OTC switches	104
Orange Book delisting	107
Research Disclosures	108

## **Chapter 5                      Case Histories                      110**

Summary	110
Introduction	111
Prozac	112
Losec and Nexium	114
Epogen v Dynepo	118
Plavix	121
Legal challenges	122
Impact of generic clopidogrel	123

## **Chapter 6                      Optimizing Revenue Returns                      126**

Summary	126
Introduction	127
Lifecycle initiatives	127
Franchise development	131
Follow on products	131
Secondary patents	132
Prodrugs	133
Portfolio development	134
Competing with generics	134

## **Chapter 7                      Future outlook                      138**

<b>Summary</b>	<b>138</b>
<b>Introduction</b>	<b>139</b>
<b>Changes in drug development</b>	<b>139</b>
Impact of technology	139
Tougher project goals	141
<b>Legislative issues</b>	<b>141</b>
KSR International Co. v. Teleflex Inc (US Supreme Court)	143
<b>Biologicals</b>	<b>144</b>

## **Appendix                      146**

<b>Glossary</b>	<b>146</b>
<b>References</b>	<b>148</b>
<b>Index</b>	<b>149</b>

## **List of Figures**

Figure 1.1:	Novel Therapeutic Entities Approved by the FDA, 2000-2006	20
Figure 1.2:	Schematic drug revenue life cycle	22
Figure 1.3:	Dependence of major companies' 2006 revenues on blockbuster products	24
Figure 1.4:	US Sales of Prozac and generic fluoxetine, 2000 – 2006	26
Figure 1.5:	Quarterly US sales of Zocor 2005-2006	27
Figure 1.6:	Quarterly US sales of Plavix 2005-2007	28
Figure 1.7:	US sales of OTC and Prescription Claritin, 2000-2006	30
Figure 2.8:	Variation in number of SPCs granted in EU countries, 2003	45
Figure 2.9:	Variation in number of SPCs granted in EU countries, 2003	47
Figure 3.10:	Impact of offensive strategies on drug revenue life cycle	67
Figure 3.11:	Primary claims of two key patents relating to paroxetine	77
Figure 4.12:	Impact of defensive strategies on drug revenue life cycle	95
Figure 4.13:	Timeline for Paragraph IV ANDA filing	97
Figure 4.14:	US sales of Paxil, an authorized generic and a competing generic August 2003- June 2004	102
Figure 4.15:	US Sales revenues of Schering-Plough's major anti-histamines 2000-2006	106
Figure 5.16:	Revenues from AstraZeneca's antiulcer franchise 1999-2006	115
Figure 6.17:	US Sales of Wellbutrin and generic bupropion 1999-2006	129
Figure 6.18:	Global sales of Adalat formulations 1975-2000	130

# List of Tables

Table 1.1:	Drugs generating 2006 revenues in excess of \$3 billion	25
Table 2.2:	Possible term extensions in major markets	43
Table 2.3:	Selected high revenue generating Orphan drugs	50
Table 2.4:	Orphan drug legislation in the major markets	51
Table 5.5:	Amgen's key Epogen patents	119